Search Results for keywords:"hearing request"

Cedarburg Pharmaceuticals has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of controlled substances. The company plans to produce synthetic Tetrahydrocannabinols (THC) as an active pharmaceutical ingredient for distribution. Interested parties, including current manufacturers or applicants, can submit comments or request a hearing regarding this application by March 15, 2021. The DEA is handling correspondence related to this application.

The Nuclear Regulatory Commission (NRC) is considering approving an export license for Curtiss-Wright Corporation to send reactor coolant pumps and components to the Sanmen Nuclear Power Plant in China. The NRC has announced a chance for the public to comment, request a hearing, or petition to intervene by May 19, 2025. Comments can be submitted online, via email, fax, or mail. Interested individuals are advised not to include personal information they do not want publicly disclosed in their comments.

The Securities and Exchange Commission (SEC) issued a notice about an application for an exemption from certain sections of the Investment Company Act of 1940. The application is from various companies, including Ares Capital Management and Ares Core Infrastructure Fund, seeking permission to offer multiple classes of shares with different sales fees for certain investment companies. The application was initially filed on January 8, 2025, and amended on February 28, 2025. The SEC will grant the requested relief unless a hearing is ordered, and interested individuals can request a hearing by April 7, 2025.

S&B Pharma, Inc. has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of certain controlled substances. The company intends to import intermediate forms of Tapentadol for manufacturing purposes and ANPP to produce other controlled substances, but they will not import finished products for commercial sale. Interested parties, such as registered manufacturers, can submit comments, objections, or request a hearing regarding this application by March 18, 2021.

The Securities and Exchange Commission (SEC) has published a notice about an application from the Coatue CTEK Fund and Coatue Management, L.L.C. These applicants are seeking an order to allow certain registered closed-end investment companies to issue multiple classes of shares, along with imposing asset-based fees and early withdrawal charges. If no hearing is requested by January 7, 2025, the SEC is set to grant the requested exemptions. Interested parties are given details on how to apply for a hearing if they wish to contest the application.

The Securities and Exchange Commission (SEC) announced that ETF Opportunities Trust and Brookmont Capital Management, LLC have applied for an exemption under the Investment Company Act of 1940. This exemption would allow them to make changes to subadvisory agreements without needing shareholder approval and to bypass certain disclosure rules about fees paid to subadvisors. The SEC will issue an order granting this request unless a hearing is requested by February 10, 2025. Interested individuals can request a hearing by contacting the SEC and providing proof of service to the applicants.

Invizyne Technologies, Inc. has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of certain controlled substances, including synthetic Tetrahydrocannabinols. Stakeholders, such as current manufacturers and applicants, can submit comments or objections electronically through the Federal eRulemaking Portal by March 24, 2025, and may also request a hearing by the same date. The DEA has provided detailed instructions for submitting comments online and has assured that comments will receive a Comment Tracking Number upon successful submission.

The Securities and Exchange Commission (SEC) has released a notice regarding an application for exemption requested by Jefferies Credit Management LLC and Jefferies Credit Partners BDC Inc. The applicants seek permission to allow certain registered closed-end investment companies to issue multiple classes of shares with different sales loads and fees. This notice provides information on how individuals can request a hearing regarding the application. Any hearing requests must be submitted to the SEC by April 8, 2025.

The Food and Drug Administration (FDA) is proposing to reject the new drug application from Vanda Pharmaceuticals for TRADIPITANT capsules, intended to treat nausea in gastroparesis. The application was found lacking as it did not provide substantial evidence of the drug’s effectiveness and safety based on submitted studies and data. Vanda has the option to request a hearing to contest this decision, though they must address all the identified deficiencies. If no hearing request is filed, or if it is not deemed substantial, the FDA will officially deny the application.

The Securities and Exchange Commission has issued a notice regarding Marqeta, Inc.'s application for an order under the Investment Company Act of 1940. Marqeta seeks to be recognized as primarily engaging in business activities other than investing in securities, focusing on providing a payment card issuing platform. The application details Marqeta's operations, historical development, and financial practices to demonstrate that it does not function as an investment company. The SEC invites interested parties to request a hearing concerning the application with a deadline in March 2025.